Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic
Home » Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic

GH AMEA on Social Media Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic
Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic
Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic
GH AMEA

Guardant Health, Inc. has announced a strategic collaboration with Janssen Biotech, Inc. to pursue regulatory approval and commercialization of the Guardant360® CDx as a companion diagnostic for amivantamab, an investigational EGFR-MET bispecific antibody being studied in the treatment of non-small cell lung cancer. The agreement covers the United States, Canada, Japan, and Europe. Click on the press release link below to find out more.

https://lnkd.in/gpw_938

Open chat
Message us